Search hospitals > California > Duarte
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Claim this profileDuarte, California 91010
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Pancreatic Cancer
Conducts research for Breast Cancer
20 reported clinical trials
1 medical researcher
Summary
City of Hope (City of Hope National Medical Center, City of Hope Medical Center) is a medical facility located in Duarte, California. This center is recognized for care of Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer and other specialties. City of Hope (City of Hope National Medical Center, City of Hope Medical Center) is involved with conducting 20 clinical trials across 75 conditions. There are 1 research doctors associated with this hospital, such as Tanya Siddiqi, MD.Area of expertise
1Lung Cancer
Stage IV
EGFR positive
KRAS positive
2Colorectal Cancer
Stage IV
KRAS positive
EGFR positive
Top PIs
Clinical Trials running at City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Lung Cancer
Pancreatic Cancer
Colorectal Cancer
Biliary Tract Cancer
Gallbladder Cancer
Bladder Cancer
Rectal Cancer
Colon Cancer
Pancreatic Carcinoma
Non-Small Cell Lung Cancer
PF-07934040 + Other Anti-Cancer Therapies
for Non-Small Cell Lung Cancer
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.
Recruiting1 award Phase 15 criteria
PF-06821497
for Small Cell Lung Cancer
This trial is testing a new drug called PF-06821497 to see if it can help adults with certain hard-to-treat cancers. The drug is taken by mouth and is being studied alone or with other treatments to check its safety and effectiveness in stopping cancer growth.
Recruiting1 award Phase 15 criteria
PF-07985045
for Cancer
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: * Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. * Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. * Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07985045) as pill by mouth. This will be repeated for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07985045 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at different times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07985045) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be in this study for up to 4 years. During this time, the participants will come into the clinic for 1 to 4 times in each 21-day or 28-day cycle. After the participants have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing
Recruiting1 award Phase 18 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at City of Hope (City of Hope National Medical Center, City of Hope Medical Center)?
City of Hope (City of Hope National Medical Center, City of Hope Medical Center) is a medical facility located in Duarte, California. This center is recognized for care of Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer and other specialties. City of Hope (City of Hope National Medical Center, City of Hope Medical Center) is involved with conducting 20 clinical trials across 75 conditions. There are 1 research doctors associated with this hospital, such as Tanya Siddiqi, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.